MedPath

Salsalate

Generic Name
Salsalate
Drug Type
Small Molecule
Chemical Formula
C14H10O5
CAS Number
552-94-3
Unique Ingredient Identifier
V9MO595C9I
Background

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

Indication

For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.

The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers

Phase 4
Completed
Conditions
Type 2 Diabetes
Diabetes
Interventions
Drug: Placebo
First Posted Date
2006-06-21
Last Posted Date
2013-03-06
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
54
Registration Number
NCT00339833
Locations
🇺🇸

NIDDK, Phoenix, Phoenix, Arizona, United States

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

Phase 2
Completed
Conditions
Cardiovascular Disease
Atherosclerosis
Insulin Resistance
Inflammation
Noninsulin-dependent Diabetes Mellitus
Interventions
Drug: Placebo
First Posted Date
2006-05-29
Last Posted Date
2020-01-21
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
71
Registration Number
NCT00330733
Locations
🇺🇸

Carl T. Hayden VA Medical Center, Phoenix, Arizona, United States

The Study of Inflammation on Blood Glucose Levels in Obese People

Phase 2
Completed
Conditions
Obesity
Interventions
First Posted Date
2005-11-24
Last Posted Date
2018-02-15
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
20
Registration Number
NCT00258115
Locations
🇺🇸

Joslin Diabetes Center, Boston, Massachusetts, United States

Effect of Salicylate on Glucose Metabolism in Insulin Resistance States

Phase 1
Completed
Conditions
Insulin Resistance
Interventions
Drug: Placebo
First Posted Date
2005-11-24
Last Posted Date
2019-04-30
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
17
Registration Number
NCT00258128
© Copyright 2025. All Rights Reserved by MedPath